PHILADELPHIA, Pennsylvania - March 18, 2019 - At Pittcon 2019, Bruker (Nasdaq: BRKR) this week highlights new and innovative analytical systems and high-value applied market solutions for food analysis, pharma applications, materials science research and quality control, clinical and preclinical research, and advances in scientific software solutions.
Frank H. Laukien, Ph.D., Bruker's President and CEO, commented: "Our new analytical instruments and solutions shown at Pittcon 2019 demonstrate the diversity and flexibility that Bruker brings to the world of laboratory science. Bruker is committed to providing the best technological solutions to meet the analytical requirements of our customers, and that includes increasing our presence in the laboratory software and applied solutions markets."
Bruker also announces minispec Form Check, a reliable and affordable TD-NMR (Time-Domain Nuclear Magnetic Resonance) solution to monitor phase purity and quantify physical API (Active Pharmaceutical Ingredient) forms including amorphization. The patent pending minispec Form Check uses 1H or 19F relaxometry data as easy-to-obtain fingerprints for expected components in solid mixtures, replacing excessive calibration, delicate sample preparation and expert know-how. In the pharma industry, API form characterization and quantification are important from drug development and formulation to manufacturing, where it is important to understand how solid API forms are influenced by production and storage.
Quantitative Performance Qualification (qPQ) for Quantitative NMR (qNMR) Applications: A collaboration between Bruker and MilliporeSigma has led to the development of certified reference materials (CRM) tailored to qNMR. A novel, two-component mixture manufactured in the ISO/IEC 17025 and ISO 17034 accreditated workflow at MilliporeSigma is the basis of the new qPQ test. This qPQ is now incorporated within the Bruker AssureSST™ software, allowing automated PQ tailored to qNMR.
The new, proprietary Honey-Profiling 2.0 Method for the Bruker NMR FoodScreener® platform now further improves the detection of sugar syrups, and considerably expands the scope of geographical and botanical honey origins that can be verified, including the popular manuka honey which is subject to frequent fraud due to its high value. The expanded 2.0 method was developed in collaboration with partners QSI and Alnumed, and features a reference database containing over 18,000 honey samples, 50 geographical origins and 100 botantical varieties. With Honey-Profiling 2.0, a comprehensive analysis of authenticity and quality is performed under automation in 25 minutes.
Bruker and Murdoch University have announced a collaboration for a phenomics center of excellence in Australia to further develop NMR and MS-based Precision Medicine Solutions. Murdoch University (www.murdoch.edu.au), the Australian National Phenome Center (ANPC, a core platform of the Western Australian Health Translation Network) and Bruker announced a memorandum of understanding for a metabolomics research and instrumentation infrastructure collaboration to develop the world's premier phenomics center for the advancement of precision medicine.
Jeremy Nicholson, Ph.D., ProVice Chancellor of Health Sciences at Murdoch University and leading the APCN, commented: "This collaboration brings state-of-the-art instruments and experienced professionals to Australia, augmenting the growing investment in precision medicine in the Asia Pacific region. Working with Bruker the ANPC at Murdoch aspire to create new disease prevention and treatment strategies through integrative studies of humans in their total environment. This will enable better understanding of gene- environment interactions that determine health status of individuals and populations. We wish to leverage key technology advantages offered by Bruker platforms and address new challenges that link precision nutrition and health programs to large scale food screening and population phenotyping. Such precise data will allow clinicians to better predict health problems and intervene earlier, saving time, money and lives. The potential of this research to provide truly personalized care is remarkable."
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology.
Please join us at Bruker's Pittcon booth # 2754 throughout the conference, and at our press conference on Tuesday, March 19, 2019, at 10:30 am to 11:30 am EDT at the Pennsylvania Convention Center, Room Banquet - 204 A.
For more information on Bruker at Pittcon 2019: https://www.bruker.com/events/pittcon/press-conference